Published in Cancer Res on January 01, 2009
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2012) 5.50
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature (2013) 3.77
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One (2011) 3.59
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med (2015) 2.55
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab (2010) 2.53
ETS gene fusions in prostate cancer. Nat Rev Urol (2009) 2.43
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol (2015) 2.32
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell (2016) 2.26
Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem (2012) 2.25
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res (2011) 2.25
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2014) 2.23
A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate (2011) 2.21
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res (2014) 2.15
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res (2014) 2.10
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene (2013) 1.86
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther (2013) 1.81
Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res (2011) 1.77
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.77
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep (2014) 1.68
Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene (2013) 1.67
An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest (2013) 1.64
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer (2015) 1.55
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res (2009) 1.52
Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res (2014) 1.51
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget (2014) 1.51
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer (2014) 1.45
Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 1.44
Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. PLoS One (2015) 1.43
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol (2011) 1.43
Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells. Cancer Res (2016) 1.41
ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer. Cancer Cell (2017) 1.38
Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res (2012) 1.35
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep (2015) 1.30
Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res (2010) 1.29
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One (2013) 1.29
The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle (2010) 1.28
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (2012) 1.28
A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci (2011) 1.27
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol (2015) 1.26
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. Cancer Res (2015) 1.24
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res (2012) 1.24
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A (2009) 1.23
Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem (2011) 1.21
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med (2011) 1.19
Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem (2013) 1.18
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res (2009) 1.17
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res (2013) 1.13
Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology (2013) 1.12
Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol (2013) 1.12
Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther (2011) 1.11
Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci (2011) 1.11
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res (2015) 1.10
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 1.08
Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol (2014) 1.08
Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate (2014) 1.07
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol (2011) 1.05
The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer (2014) 1.05
Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. Am J Clin Exp Urol (2015) 1.05
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol (2012) 1.02
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res (2011) 1.02
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate (2012) 1.01
Decoding the androgen receptor splice variants. Transl Androl Urol (2013) 1.01
AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia (2013) 1.00
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol (2012) 1.00
Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate (2012) 1.00
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol (2011) 0.99
Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids (2013) 0.99
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget (2015) 0.98
Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab (2009) 0.97
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene (2014) 0.97
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab (2011) 0.96
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer (2011) 0.96
ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem (2009) 0.96
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Molecular biology of the androgen receptor. J Clin Oncol (2002) 5.08
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression. Genes Dev (2006) 3.18
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res (2002) 2.99
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem (1994) 2.35
Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res (2007) 1.97
Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer (2006) 1.88
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer (2004) 1.54
Isoform/variant mRNAs for sex steroid hormone receptors in humans. Trends Endocrinol Metab (2003) 1.33
Complete androgen insensitivity due to deletion of exon C of the androgen receptor gene highlights the functional importance of the second zinc finger of the androgen receptor in vivo. Mol Endocrinol (1992) 1.20
New drugs in prostate cancer. Curr Opin Urol (2006) 1.08
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Characterization of Pb(In(12)Nb(12))O(3)-Pb(Mg(13)Nb(23))O(3)-PbTiO(3) ferroelectric crystal with enhanced phase transition temperatures. J Appl Phys (2008) 7.49
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Electromechanical characterization of [Formula: see text] crystals as a function of crystallographic orientation and temperature. J Appl Phys (2009) 3.80
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods (2013) 3.63
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol (2008) 3.43
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther (2005) 3.28
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
Complete set of material constants of Pb(In(12)Nb(12))O(3)-Pb(Mg(13)Nb(23))O(3)-PbTiO(3)single crystal with morphotropic phase boundary composition. J Appl Phys (2009) 3.22
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell (2013) 2.63
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol (2011) 2.62
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet (2013) 2.47
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate (2007) 2.37
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35